Skip to main content

Advertisement

Table 5 Specific adverse events (treatment related) in comparisons with placebo

From: Sildenafil (Viagra) for male erectile dysfunction: a meta-analysis of clinical trial reports

    Number (%) with outcome  
Dosing (mg) Number of trials Adverse event Sildenafil Placebo Relative risk (95% CI) NNH (95% CI)
25 3 Dyspepsia 4/312 (1.2) 1/426 (0.2) 4.4 (0.6 to 34)
   Headache 31/312 (10) 14/426 (3.2) 3.1 (1.6 to 6.1) 15 (9.6 to 34)
   Vasodilation 30/312 (9.6) 4/426 (1.0) 11 (3.8 to 29) 12 (8.3 to 19)
50 5 Dyspepsia 24/511 (4.7) 4/607 (0.7) 6.4 (2.4 to 17) 24 (17 to 47)
   Headache 77/511 (15) 21/607 (0.3) 4.5 (2.8 to 7.3) 8.6 (6.6 to 12)
   Vasodilation 94/511 (18) 11/607 (1.8) 9.7 (5.4 to 18) 6.0 (5.0 to 7.7)
100 5 Dyspepsia 60/506 (12) 4/607 (0.7) 15 (5.8 to 40) 8.9 (7.1 to 12)
   Headache 115/506 (23) 21/607 (0.3) 6.8 (4.3 to 11) 5.2 (4.3 to 6.5)
   Vasodilation 90/506 (17) 11/607 (1.8) 9.2 (5.0 to 17) 6.3 (5.1 to 8.0)
200 2 Dyspepsia 35/191 (18) 3/181 (1.7) 11 (3.5 to 35) 6.0 (4.5 to 9.2)
   Headache 62/191 (32) 7/181 (3.9) 8.4 (4.0 to 18) 3.5 (2.8 to 4.7)
   Vasodilation 43/191 (22) 7/181 (3.9) 5.9 (2.7 to 13) 5.4 (4.0 to 8.3)
Dose optimised 5 Dyspepsia 24/517 (4.6) 7/524 (1.3) 3.4 (1.5 to 7.9) 31 (19 to 82)
   Headache 63/517 (12) 10/524 (1.9) 6.3 (3.2 to 12) 9.8 (7.5 to 14)
   Vasodilation 65/517 (13) 4/524 (0.8) 16 (6.0 to 44) 8.5 (6.7 to 11)